Randomized trial · people

Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In early testing in type 2 diabetes, the higher retatrutide doses lowered blood sugar and weight versus placebo over 12 weeks, with gut side effects the most common complaint.

Kind
Randomized trial
Studied in
People
Number studied
72
Published
2022
Journal
Lancet

What they tested

The team tested whether weekly shots of retatrutide (LY3437943) were safe and tolerable in people with type 2 diabetes, and how the drug behaved in the body and affected blood sugar and weight.

How the study was done

A randomized, double-blind, placebo-controlled phase 1b trial in 72 adults with type 2 diabetes at four US centers, who got weekly injections for 12 weeks. People received one of five rising retatrutide doses, placebo (a dummy shot), or dulaglutide 1.5 mg, with the two highest doses reached by stepping up over time.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Side effects that started during treatment affected 33 (63%) people on retatrutide, 60% of those on dulaglutide and 54% of those on placebo, and stomach and gut problems were the most common. The drug's half-life, the time for half of it to leave the body, was about 6 days. Compared with placebo at week 12, the 3 mg, 3/6 mg and 3/6/9/12 mg groups lowered average daily blood sugar by 2.8, 3.1 and 2.9 mmol/L, and lowered sHbA1c, a measure of average blood sugar, by 1.4%, 1.6% and 1.2%. Weight loss seemed to rise with dose, reaching 8.96 kg more than placebo in the 3/6/9/12 mg group.

What it doesn’t show

This was a small, 12-week early-phase trial built mainly to check safety, with small groups at each retatrutide dose and 29 people leaving the study early. It was funded by Eli Lilly and Company.

The paper

Urva et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo